Literature DB >> 3458229

Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo.

D Aragnol, L D Leserman.   

Abstract

In a study designed to evaluate the potential for in vivo manipulation of the circulation and tissue distribution of injected liposomes, mice were passively injected with antidinitrophenyl (anti-DNP) monoclonal antibodies of the IgG2a or IgG2b subclasses or were immunized with the nitrophenyl hapten bound to a protein carrier. They were then injected i.v. with 125I- and carboxyfluorescein-labeled, DNP-bearing liposomes. Circulation time of the DNP-bearing liposomes was markedly reduced in actively and passively immune mice, with increased deposition of liposomes in the liver. The increased clearance of liposomes could be abrogated by injection of a monoclonal antibody directed against the murine IgG Fc receptor (2.4G2). The results suggest that clearance of ligand-bearing reagent in the face of an immune response may be modified by specific immunologic manipulation in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3458229      PMCID: PMC323367          DOI: 10.1073/pnas.83.8.2699

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  On the molecular basis of T-helper-cell function. IV. B-lymphocyte-promotor factors: on their mode of action, biochemical nature and possible relationship to molecules involved in specific T-helper-cell activity.

Authors:  L Reininger; J Fueri; A Boned; M Prat; S Landolfo; B Rubin
Journal:  Cell Immunol       Date:  1985-04-15       Impact factor: 4.868

2.  A receptor for Fc on mouse B-lymphocytes.

Authors:  F Paraskevas; S T Lee; K B Orr; L G Israels
Journal:  J Immunol       Date:  1972-05       Impact factor: 5.422

3.  The subclass specificity for the binding of murine myeloma proteins to macrophage and lymphocyte cell lines and to normal spleen cells.

Authors:  D M Segal; J A Titus
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

4.  Specific antibody-dependent phagocytosis of lipid vesicles by RAW264 macrophages results in the loss of cell surface Fc but not C3b receptor activity.

Authors:  H R Petty; D G Hafeman; H M McConnell
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

5.  Liposome disposition in vivo: effects of pre-dosing with lipsomes.

Authors:  R M Abra; M E Bosworth; C A Hunt
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1980-08

6.  Monoclonal antibody covalently coupled with fatty acid. A reagent for in vitro liposome targeting.

Authors:  A Huang; L Huang; S J Kennel
Journal:  J Biol Chem       Date:  1980-09-10       Impact factor: 5.157

7.  Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab')2 to vesicle surface.

Authors:  T D Heath; R T Fraley; D Papahdjopoulos
Journal:  Science       Date:  1980-10-31       Impact factor: 47.728

8.  Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro.

Authors:  C Kirby; J Clarke; G Gregoriadis
Journal:  Biochem J       Date:  1980-02-15       Impact factor: 3.857

9.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

10.  Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.

Authors:  J C Unkeless
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

View more
  16 in total

Review 1.  Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems.

Authors:  Patrick M Glassman; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2019-03-05       Impact factor: 4.030

Review 2.  Unintended effects of drug carriers: Big issues of small particles.

Authors:  Hamideh Parhiz; Makan Khoshnejad; Jacob W Myerson; Elizabeth Hood; Priyal N Patel; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

3.  Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting.

Authors:  Colin F Greineder; Carlos H Villa; Landis R Walsh; Raisa Y Kiseleva; Elizabeth D Hood; Makan Khoshnejad; Robert Warden-Rothman; Andrew Tsourkas; Vladimir R Muzykantov
Journal:  Bioconjug Chem       Date:  2017-12-29       Impact factor: 4.774

Review 4.  Liposomes. Opportunities in drug delivery.

Authors:  T M Allen
Journal:  Drugs       Date:  1997       Impact factor: 9.546

5.  Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo.

Authors:  O Ishida; K Maruyama; H Tanahashi; M Iwatsuru; K Sasaki; M Eriguchi; H Yanagie
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

6.  Molecular engineering of high affinity single-chain antibody fragment for endothelial targeting of proteins and nanocarriers in rodents and humans.

Authors:  Colin F Greineder; Elizabeth D Hood; Anning Yao; Makan Khoshnejad; Jake S Brenner; Ian H Johnston; Mortimer Poncz; Claudia Gottstein; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2016-02-06       Impact factor: 9.776

7.  Brain drug delivery of small molecules using immunoliposomes.

Authors:  J Huwyler; D Wu; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

8.  A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo.

Authors:  S A Longman; P R Cullis; L Choi; G de Jong; M B Bally
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Lipid composition is important for highly efficient target binding and retention of immunoliposomes.

Authors:  K Maruyama; S J Kennel; L Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

10.  Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.

Authors:  A Mori; S J Kennel; M van Borssum Waalkes; G L Scherphof; L Huang
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.